San Francisco, California, September 28, 2018: A recent report by TMR Research, titled, “West Nile Virus Infection Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025,” states that West Nile Virus is an epidemic in Africa, Asia, Europe, the U.S., Australia, and the Middle East. The young children, the aged, and those afflicted with HIV and immunosuppression are highly prone to acquiring the disease.
The report then goes on to add that the global West Nile Virus infection treatment market is primed to rise owing to a large population of elderly worldwide, whose number will only increase in the days to come. Nevertheless, a major challenge the global West Nile Virus infection treatment market has to overcome is the dearth of sufficient knowledge about the malady among people. Apart from that, absence of infection specific treatment are also hampering the market.
Get Sample Copy of this Report @
The report on the global West Nile Virus infection market informs that at present a specific course of treatment is not available in the market. This, however, has opened new growth avenues for keen players. They are now seen working on developing infection specific drugs. Hu-E16 monoclonal antibody procured from plant, leukocyte procured from interferon alfa-n3 in humans, CEL -1000, HBV -002, BG-323, VG-WNV, and ETX-112 are some of the potential drugs that are in the trial phase at present in the market.
From a geographical standpoint, Europe and North America lead the global West Nile virus infection treatment market. This is mainly because of the superior healthcare infrastructure, increased awareness about the malady, and higher public and private allocations for research and development programs devoted to finding better cures of the infection in the regions.
Read Comprehensive Overview of Report @
Some of the key players in the global West Nile virus infection treatment market that have been profiled in the report are Hemispherx Biophrma Inc., Kineta Inc., Hawaii Biotech Inc., and CEL-SCI Corporation.